Oshi, M.; Takahashi, H.; Tokumaru, Y.; Yan, L.; Rashid, O.M.; Nagahashi, M.; Matsuyama, R.; Endo, I.; Takabe, K.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer. Cells 2020, 9, 1643.
https://doi.org/10.3390/cells9071643
AMA Style
Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M, Matsuyama R, Endo I, Takabe K.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer. Cells. 2020; 9(7):1643.
https://doi.org/10.3390/cells9071643
Chicago/Turabian Style
Oshi, Masanori, Hideo Takahashi, Yoshihisa Tokumaru, Li Yan, Omar M. Rashid, Masayuki Nagahashi, Ryusei Matsuyama, Itaru Endo, and Kazuaki Takabe.
2020. "The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer" Cells 9, no. 7: 1643.
https://doi.org/10.3390/cells9071643
APA Style
Oshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Nagahashi, M., Matsuyama, R., Endo, I., & Takabe, K.
(2020). The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer. Cells, 9(7), 1643.
https://doi.org/10.3390/cells9071643